Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that has recently been approved for the treatment of obesity as well. Semaglutide is postulated to be a promising candidate for the treatment of non-alcoholic steatohepatitis (NASH). Here, Ldlr-/-.Leiden mice rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Inia, José A., Stokman, Geurt, Morrison, Martine C., Worms, Nicole, Verschuren, Lars, Caspers, Martien P. M., Menke, Aswin L., Petitjean, Louis, Chen, Li, Petitjean, Mathieu, Jukema, J. Wouter, Princen, Hans M. G., van den Hoek, Anita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218334/
https://www.ncbi.nlm.nih.gov/pubmed/37239841
http://dx.doi.org/10.3390/ijms24108494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218334/
https://www.ncbi.nlm.nih.gov/pubmed/37239841
http://dx.doi.org/10.3390/ijms24108494

Ejemplares similares